Hydrosalpinx

Summary

Hydrosalpinx (MONDO:0600025) is a disease and 10 clinical trials. Top therapeutic interventions include gonadorelin acetate, triptorelin, and isopentyl 2-cyanoacrylate. A subtype of fallopian tube disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hydrosalpinx
Mondo ID	MONDO:0600025
ICD-11	1766606192
NCIT	C142886
UMLS	C0221376
MedGen	526227
Is cancer (heuristic)	no

Also known as: blocked fallopian tube · fallopian tube obstruction

Disease family

This is a subtype of fallopian tube disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › fallopian tube disorder › hydrosalpinx

Related subtypes (5): fallopian tube endometriosis, salpingitis, fallopian tube neoplasm, embryonic cyst of fallopian tube, tubal pregnancy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE1/PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02977234	PHASE1/PHASE2	UNKNOWN	Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04432467	PHASE1/PHASE2	COMPLETED	Fertility Restoration Using Autologous Mesenchymal Stem Cells
NCT07351747	Not specified	RECRUITING	Effect of Laser Acupoints on Fallopian Tube Obstruction
NCT03395301	Not specified	UNKNOWN	Coil Hysteroscopic Tubal Occlusion in the Treatment of Hydrosalpinx
NCT03521128	Not specified	WITHDRAWN	Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment
NCT03703401	Not specified	COMPLETED	The Role of Hydrosalpinx in Recurrent Miscarriage
NCT03854292	Not specified	COMPLETED	Hydrosalpinx Management Before Intracytoplasmic Sperm Injection
NCT04335864	Not specified	COMPLETED	Comparing the Impact of 2 Different Techniques in Management of Hydrosalpinx on Pregnancy Rates Following ICSI
NCT05195073	Not specified	COMPLETED	Three Dimensional Versus Two Dimensional Laparoscopic Salpingectomy in Patients With Hydrosalpinx Undergoing IVF-ET

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GONADORELIN ACETATE	4	1
TRIPTORELIN	4	1
ISOPENTYL 2-CYANOACRYLATE	2	1
CHEMBL2370644	0	1